A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects

Completed · Phase 2 · Has a placebo group

Conditions studied: Diabetes Mellitus, Type 2

In brief

The purpose of this clinical research study is to assess the safety of, exposure to, and biological effects of BMS-512148 in stable Type 2 diabetic subjects

Key facts

Study ID

NCT00162305

Run by

AstraZeneca

People needed

47

Starts

2005-04-01

Expected to finish

2005-08-01

Last updated by the study team

2016-10-27

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Established diagnosis of Type 2 diabetes mellitus, who are treated with metformin or diet alone (drug naive).
• Fasting glucose (FG) < - 240 mg/dL, while on metformin or antidiabetic diet alone.
• HbA1c (Hemoglobin A1c) in the range of 6.0-10.0%

You may not qualify if…

• Women of childbearing potential

Where it is running

• Local Institution — Fort Lauderdale, Florida, United States
• Local Institution — Miami, Florida, United States
• Local Institution — Orlando, Florida, United States
• Local Institution — New Orleans, Louisiana, United States
• Local Institution — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.